However, with the government having to tackle its budgetary debts, further increases in funding for its programs may be under threat. In this article, I look at the relative share valuations of two top competitors in this sector, comparing their fundamental performance, and suggesting the trade to buy WellPoint Inc. (WLP) and to sell UnitedHealth Group (NYSE:UNH).
WellPoint Inc. (WLP)
Shares are currently trading around $72, in the middle of their 52-week price range of $56.61 to $81.92.
Earnings per share for the last 12 months are $7.61, and these are expected to reach $7.75 in its next fiscal year (ending December 2012). These numbers place the shares on a trailing P/E ratio of 9.5 and a forward multiple around 9.
WLP paid a dividend of $1.00 last year, which was covered 7.5 times by its earnings. At the current market price, the payment of this level of dividend offers investors a yield of 1.4%. Current operating margin at WLP is 8%, and revenue as stated in its last income statement was $60 billion. Revenues grew by 6% last quarter compared with the same period last year.
WLP holds cash of $20 billion, and has debts totaling $10.7 billion. Its debt to equity ratio is 45. Servicing its operations and debt, its operating cash flow through the last 12 months has been $3.9 billion. The reported book value of the stock is $67 per share, placing the shares on a premium to book value of 10%.
Analysts' median price target for the stock is $87, implying an upside from the current market price.
WLP shares have out-performed the S&P 500 Index through the last 12 months, though the price fell more heavily than the market when equity prices collapsed in August. Prior to the August 2011 U.S. debt rating debacle, shareholders had been sitting on a share price rise of over 40% from October last year. This paper profit has been cut to a mere 18% now.
The company has again extended its share repurchase program by $5 billion, and it will use this authorization over the coming years as it sees market and industry conditions offering value by doing so. In the first half of 2011, it repurchased 20.8 million shares at a cost of $1.5 billion. Shareholders criticized the company for doing this rather than paying a dividend. The company responded by announcing quarterly dividends of $0.25 per share going forward.
WLP announced last fall that it has been awarded a major Medicaid contract worth an estimated $273 million, to which shares have reacted positively.
UnitedHealth Group Inc. (NYSE:UNH)
Shares are currently trading around $53, in the upper quartile of their 52-week price range of $38.93 to $53.50.
Earnings per share for the last 12 months were $4.51, and these are expected to reach $4.77 in its next fiscal year (ending December 2012). These numbers place the shares on a trailing P/E ratio of 11, and a forward multiple of 10.
UNH paid a dividend of $0.65 last year, which was covered seven times by its earnings. At the current market price, the payment of this level of dividend offers investors a yield of 1.2%. Current operating margin at WLP is 8%, and revenue per share as stated in its last income statement was around $90. Revenues grew by 7% last quarter compared with the same period last year.
UNH holds cash of $16.4 billion, and has debts totaling $12 billion. Its debt to equity ratio is 43. Servicing its operations and debt, its operating cash flow through the last 12 months has been $8.8 billion. The reported book value of the stock is $26 per share, placing the shares on a premium to book value of approximately 100%.
Analysts' median price target for the stock is $59, implying an upside from the current market price of 20%.
UNH shares have traded very positively over the last 12 months, and shareholders have been rewarded with a capital return of over 30% in this time. As with the broader market, shares fell back in August, though did not suffer as much as industry competitors.
Recent news has been mixed at UNH, though the shares continue to push ahead.
Avalere, a consulting firm based in Washington, said that a study has shown UNH may lose 500,000 enrollees from its Medicare drug plans this year, as premium increases price it out of the market.
Also last year, CEO Stephen Hemsley told analysts that he expected earnings to grow in 2012, though high unemployment rates, growing care use and the healthcare overhaul would pressure performance. He is said to have cited "a laundry list" of negatives without any equal positives.
Basis For Investment
Looking at the 12-month chart, it is clear that UNH shares have out-performed WLP shares since August. On the basis of share price trading patterns, news flow from the two companies, and company fundamentals, I think that this gap in performance has stretched too far, and will reverse over the coming weeks/months.
I see no justification for WLP shares to trade on a lower forward price to earnings ratio than that of UNH. Operating margins are of equivalent strength, as is the debt to equity ratio of the two companies. WLP has recently won a large Medicare contract, while UNH has warned that the healthcare review will harm its results. UNH has also stressed that other factors will likely pressure its results gong forward.
WLP has introduced a dividend, having listened to the concern of shareholders, which will attract dividend investors. I see its share repurchase program as offering support to the share price and added value to shareholders.
From analysts' forecasts, the implied upside of WLP shares from their current level is better than the upside for WLP. WLP shares also trade on a lower premium to reported book value than UNH.
For all these reasons, I think the time is right to buy WLP. On a relative basis, I'd sell UNH.